Neurology News
-
Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today that it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s ...
-
DiamiR Biosciences Announces Participation in Alzheimer`s Panel at the BioFuture 2022 Conference
DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that the company's management will participate in the BioFuture Conference being held on November 7-9, 2022 at the Lotte New York Palace in New York City, NY. Kira Sheinerman, Ph.D., Co-Founder and Executive Director, will be a participant in the panel discussion, "New approvals, ...
By DiamiR
-
Differences Between Spinal Blocks & Epidurals
The biggest difference between spinal blocks vs epidurals is their amount of pain relief: spinal blocks provide total pain relief, while epidurals provide partial pain relief. The reason for this difference is that the former is an anesthetic, while the latter is an analgesic—no sensation versus no pain. But pain elimination comes with a total lack of feeling in the lower body, due to ...
-
Cercare Perfusion Featured on TV4’s Morning News
Last week Tobias Granberg, a Swedish researcher from Karolinska Institutet, appeared on TV4 Nyhetsmorgon together with his colleague Miia Kivipelto to share the results of their research where they investigated the influence of COVID-19 on the brain using, among others, Cercare Perfusion. The research shows changes in brain tissue vasculature in patients with long COVID-19. Continued ...
-
Orion Receives Funding to Advance its Lead GPCR-Targeted Therapeutic
Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced that it is receiving advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The ...
-
CVRx Launches new Barostlm NE02 Implantable Pulse Generator
The new Borostim NE02 Implantable Pulse Generator (IPG) launches in the U.S., improving the patient experience while on therapy and simplifying the implant procedure for physicians MINNEAPOLIS, Nov. 3, 2022 - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim NE02™ IPG. ...
By CVRx
-
VeriSIM Life Named “Predictive Analytics Solution of the Year” by BioTech Breakthrough
VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced it has been selected as the winner of the “Predictive Analytics Solution of the Year" in the BioTech Breakthrough Awards program conducted by BioTech Breakthrough. Biotech Breakthrough is a leading independent ...
By VeriSIM Life
-
Creative Enzymes Expands Its Probiotic Portfolio
Creative Enzymes, a professional enzyme provider located in New York, USA, is always hammering away at research and trials in order to provide customers with enzyme services and products with its greatest effort. With the continuous expansion of business areas and scales, the company has set foot in other areas, established a sound probiotic production and supply chain, and is pleased to announce ...
-
Elucid Appoints Dr. Michael Lesh to Board of Directors
BOSTON, November 3, 2022 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors. “We look forward to what Dr. Lesh will bring to the board with his extensive background as a cardiologist, medtech ...
By Elucid
-
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the completion of its study assessing the effect of food on absorption of its lead candidate CTx-1301, an investigational medication for the ...
By Cingulate
-
electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA-cleared, non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within selected managed care health systems. ...
-
Altoida to Present at Upcoming Industry Conferences
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, 10:30 – 11:30 am ET Location: ...
-
BESA Connectivity 2.0 preview
BESA Connectivity 2.0 is just around the corner! As a successor to the best-in-class tool for functional brain connectivity analysis, it comes with a bunch of great new features and improvements. Here are some of the most important news about this software*: Batch processing for both time-frequency and connectivity workflows – analyze your complete subject set in one go, also for ...
By BESA GmbH
-
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022
LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative technologies, today announced that a new drug candidate for NASH was selected for an oral presentation at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting 2022, to be held November 4-8 in Washington DC. As part of the presentation, LISCure ...
-
CD Formulation: One-Stop Pharmaceutical Formulation Solution Makes Drug Development Faster, Easier and More Cost-Effective
Appropriate drug formulation is a prerequisite for successful drug development. CD Formulation, a highly specialized CRO service provider, recently announced its capability of offering one-stop pharmaceutical formulation solutions that can make drug development faster, easier, and more cost-effective. Drug formulation, or pharmaceutical formulation, is a universal challenge faced by biotech ...
-
STALICLA announces first patients enrolled in EU/US multicenter data collection biosampling study
The launch of the STA-B-001 study will accelerate the recruitment of participants for STP1 and STP2 Phase 2 trials. The multicenter trial will also enable deep clinical and biological data collection to strengthen STALICLA’s platform. Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine ...
By STALICLA
-
CD Bioparticles Introduces Hydrophilic Coatings for Medical Applications
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, recently introduced hydrophilic coatings and related services for medical applications, which can be used within interventional medical devices of the cardiovascular, circulatory, nervous, urinary, and vascular system. Functional medical coatings are a class of interface materials applied to the ...
-
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has executed a Master Services Agreement (MSA) with Societal CDMO, Inc. (NASD: SCTL), a bi-coastal contract development and manufacturing ...
By Cingulate
-
Aurora BioPharma to Attend Pioneers 2017 at the Mandarin Oriental Hotel in New York
Aurora BioPharma, Inc., a clinical stage biotechnology company developing a breakthrough in cancer treatment, announced today that company CEO and President, Robert Brooks, will attend Pioneers 2017 presented by Joseph Gunnar & Co., LLC taking place Tuesday May 2nd at the Mandarin Oriental Hotel in New York. About Joseph Gunnar & Co., LLC Joseph Gunnar & Co., LLC was founded in 1997 ...
-
Aurora BioPharma To Join In On A Presentation And Discussion On The GBM AGILE Trial At The Ritz-Carlton, Pentagon City
Aurora BioPharma, Inc., a clinical stage biotechnology company developing a breakthrough in cancer treatment, announced today that company CEO and President, Robert Brooks, will join in on a presentation and discussion of the GBM AGILE (Adaptive, Global, Innovative, Learning Environment) trial. The meeting is being held at the Ritz Carlton, at Fashion Centre at Pentagon City, April 11th. About ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you